Knight Jeff E. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jul 17, 2024
Insider Transaction Report
Form 4
Knight Jeff E.
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock option (Right to Buy)
2024-07-15−17,499→ 112,501 totalExercise: $23.98Exp: 2031-09-01→ Common Stock (17,499 underlying) - Exercise/Conversion
Common Stock
2024-07-15$23.98/sh+17,499$419,626→ 70,079 total - Exercise/Conversion
Stock option (Right to Buy)
2024-07-15−2,887→ 20,213 totalExercise: $20.02Exp: 2032-02-29→ Common Stock (2,887 underlying) - Exercise/Conversion
Stock option (Right to Buy)
2024-07-15−5,687→ 85,313 totalExercise: $19.64Exp: 2033-03-01→ Common Stock (5,687 underlying) - Exercise/Conversion
Common Stock
2024-07-15$19.64/sh+5,687$111,693→ 78,653 total - Sale
Common Stock
2024-07-15$55.00/sh−27,000$1,485,000→ 51,653 total - Exercise/Conversion
Common Stock
2024-07-15$20.02/sh+2,887$57,798→ 72,966 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- [F3]1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- [F4]1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.